How mature is your Data & AI organization?Take the diagnostic
All use cases

AI USE CASE

Patent Expiry Lifecycle Strategy Optimizer

Help pharma strategists defend revenue and plan generic entry response using AI-driven patent intelligence.

Typical budget
€120K–€400K
Time to value
24 weeks
Effort
20–40 weeks
Monthly ongoing
€8K–€25K
Minimum data maturity
intermediate
Technical prerequisite
ml team
Industries
Healthcare
AI type
nlp, forecasting

What it is

Combines NLP-based patent landscape analysis with predictive analytics on competitor pipelines and market data to optimize lifecycle management decisions. Pharma companies typically face 20–40% revenue erosion within 12 months of loss of exclusivity; this approach can extend branded revenue windows by identifying reformulation, new indication, or authorized generic opportunities 18–36 months in advance. Teams gain structured competitive intelligence from unstructured patent filings, FDA submissions, and pricing data, reducing manual research effort by 50–70%. Outputs feed directly into portfolio investment decisions and generic entry defense playbooks.

Data you need

Historical patent filing data, competitor pipeline databases, FDA/EMA submission records, and product-level market and pricing data spanning at least 5 years.

Required systems

  • data warehouse
  • erp

Why it works

  • Establish a dedicated IP and competitive intelligence data pipeline before model development begins.
  • Involve medical affairs, regulatory, and commercial strategy teams early to ensure outputs map to real decision points.
  • Build explainability layers so strategists can trace why a specific defense option is ranked highest.
  • Run quarterly model retraining cycles aligned with patent filing and regulatory submission calendars.

How this goes wrong

  • Patent and competitor pipeline data is incomplete or not systematically collected, making model outputs unreliable.
  • Strategic recommendations are not trusted by senior teams if the AI rationale is opaque — low explainability kills adoption.
  • Integration with portfolio investment workflows is skipped, leaving outputs as reports that no one acts on.
  • Model trained on historical patent landscapes becomes stale as regulatory and IP environments shift rapidly.

When NOT to do this

Do not pursue this if your organisation lacks a structured patent data governance process and a cross-functional strategy team willing to operationalise model outputs — the analysis will sit unused.

Vendors to consider

Sources

This use case is part of a larger Data & AI catalog built from 50+ enterprise transformation programs. Take the free diagnostic to see how it ranks against your specific context.